Lee's Pharma in deal with Nippon Shinyaku

Hong Kong-based Lee's Pharmaceutical, an integrated research-driven and market-oriented drug group in China, has signed a license agreement with  Nippon Shinyaku for a pharmaceutical product containing the latter's  antibacterial agent prulifloxacin.

Under the accord, Lee's is granted exclusive marketing rights for  prulifloxacin products in China. The group has paid Nippon Shinyaku an  upfront amount, and will make milestone payments based on the sales  achievement and royalties on sales.

Prulifloxacin, which was discovered by Nippon Shinyaku, is an oral  quinolone antibacterial agent that has been launched in Japan and  Europe. In addition, Nippon Shinyaku has already concluded license  agreements with companies in South Korea and the USA to develop  prulifloxacin in their territories.